STAINES, England, March 24, 2011 /PRNewswire/ -- The Astellas European Foundation has today announced financial support to the Japanese Red Cross Society for their work to assist those impacted by the earthquake and tsunami on Friday, 11th March. The Japanese Red Cross Society is working with the local government of the affected region and the support will help provide aid to the local population.
Mr. Ken Jones, Chief Operating Officer of Astellas Pharma Europe Ltd. and a Trustee of the Astellas European Foundation said, "We are deeply saddened by the earthquake and subsequent events in Japan. I would like to thank the large number of people who have contacted Astellas to express their concern for our employees, and for the many people affected by the earthquake and tsunami . The Japanese Red Cross is doing incredible work in the region and we pledge our support to their vital efforts."
The support from the Astellas European Foundation is supplementary to donations by Astellas Pharma Inc., headquartered in Japan, to the Japanese Red Cross Society and by the Astellas USA Foundation to the relief work.
Our thoughts remain with those in Japan as the country continues to deal with this crisis.
Notes to Editors
About The Astellas European Foundation
The Astellas European Foundation is a registered charity, formed in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation also supports Astellas employees in their fundraising efforts for charitable causes. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.
About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 3,900 staff across these regions.
SOURCE The Astellas European Foundation